Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway September 28, 2021 01:37 Regulatory Read more
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease June 23, 2021 22:11 Regulatory Read more
The Nomination Committee’s proposal for the election of board members in BioArctic AB February 12, 2021 08:00 Regulatory Read more
